JP2020522473A5 - - Google Patents

Download PDF

Info

Publication number
JP2020522473A5
JP2020522473A5 JP2019564917A JP2019564917A JP2020522473A5 JP 2020522473 A5 JP2020522473 A5 JP 2020522473A5 JP 2019564917 A JP2019564917 A JP 2019564917A JP 2019564917 A JP2019564917 A JP 2019564917A JP 2020522473 A5 JP2020522473 A5 JP 2020522473A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
variable domain
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019564917A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020522473A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/034223 external-priority patent/WO2018217947A1/en
Publication of JP2020522473A publication Critical patent/JP2020522473A/ja
Publication of JP2020522473A5 publication Critical patent/JP2020522473A5/ja
Priority to JP2023172090A priority Critical patent/JP2024012297A/ja
Withdrawn legal-status Critical Current

Links

JP2019564917A 2017-05-23 2018-05-23 Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍関連抗原に結合するタンパク質 Withdrawn JP2020522473A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023172090A JP2024012297A (ja) 2017-05-23 2023-10-03 Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍関連抗原に結合するタンパク質

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201762510173P 2017-05-23 2017-05-23
US62/510,173 2017-05-23
US201762539419P 2017-07-31 2017-07-31
US201762539396P 2017-07-31 2017-07-31
US201762539416P 2017-07-31 2017-07-31
US62/539,396 2017-07-31
US62/539,419 2017-07-31
US62/539,416 2017-07-31
US201762546296P 2017-08-16 2017-08-16
US201762546292P 2017-08-16 2017-08-16
US62/546,296 2017-08-16
US62/546,292 2017-08-16
US201762552146P 2017-08-30 2017-08-30
US62/552,146 2017-08-30
PCT/US2018/034223 WO2018217947A1 (en) 2017-05-23 2018-05-23 A protein binding nkg2d, cd16 and a tumor-associated antigen

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023172090A Division JP2024012297A (ja) 2017-05-23 2023-10-03 Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍関連抗原に結合するタンパク質

Publications (2)

Publication Number Publication Date
JP2020522473A JP2020522473A (ja) 2020-07-30
JP2020522473A5 true JP2020522473A5 (enExample) 2021-07-26

Family

ID=64395887

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019564917A Withdrawn JP2020522473A (ja) 2017-05-23 2018-05-23 Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍関連抗原に結合するタンパク質
JP2023172090A Pending JP2024012297A (ja) 2017-05-23 2023-10-03 Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍関連抗原に結合するタンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023172090A Pending JP2024012297A (ja) 2017-05-23 2023-10-03 Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍関連抗原に結合するタンパク質

Country Status (11)

Country Link
US (1) US20200157227A1 (enExample)
EP (1) EP3630169A4 (enExample)
JP (2) JP2020522473A (enExample)
KR (2) KR20200010430A (enExample)
CN (1) CN111278455A (enExample)
AU (1) AU2018271930B2 (enExample)
BR (1) BR112019024632A2 (enExample)
CA (1) CA3064714A1 (enExample)
IL (1) IL270803B2 (enExample)
MX (1) MX2019014000A (enExample)
WO (1) WO2018217947A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110944651A (zh) 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
EP4273258A3 (en) 2017-02-20 2024-01-17 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
MX2020008333A (es) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
CA3090244A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
CN112119093A (zh) 2018-02-20 2020-12-22 蜻蜓治疗公司 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
CA3108427A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
CN113164570B (zh) 2018-08-08 2024-05-14 蜻蜓疗法股份有限公司 结合nkg2d、cd16和肿瘤相关抗原的蛋白质
CN114555117A (zh) * 2019-10-12 2022-05-27 百奥泰生物制药股份有限公司 抗cd20抗体制剂及抗cd20抗体在治疗cd20阳性疾病中的应用
AU2021268340A1 (en) 2020-05-06 2022-12-08 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and CLEC12A
CN114057874B (zh) * 2020-07-31 2023-05-05 北京市神经外科研究所 抗cd44的单链抗体及其在制备治疗肿瘤的药物中的用途
CN114057875B (zh) * 2020-07-31 2023-05-05 北京市神经外科研究所 抗cd133的单链抗体及其在制备治疗肿瘤的药物中的用途
EP4225792A1 (en) * 2020-10-08 2023-08-16 Affimed GmbH Trispecific binders
PL244438B1 (pl) * 2020-12-28 2024-01-29 Inst Biochemii I Biofizyki Polskiej Akademii Nauk Peptyd do stosowania w leczeniu lub zapobieganiu COVID-19
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
JP2024524378A (ja) * 2021-06-29 2024-07-05 山▲東▼先声生物制▲薬▼有限公司 Ｃｄ１６抗体及びその応用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1266014A2 (en) * 2000-03-24 2002-12-18 Peter Kufer Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
DE10261223A1 (de) * 2002-12-20 2004-07-08 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Steigerung der Immunantwort durch Substanzen, welche die Funktion von Natürlichen Killerzellen beeinflussen
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
WO2009077483A1 (en) * 2007-12-14 2009-06-25 Novo Nordisk A/S Antibodies against human nkg2d and uses thereof
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
WO2011143545A1 (en) * 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
JP2013537416A (ja) * 2010-08-13 2013-10-03 メディミューン リミテッド 変異型Ｆｃ領域を含むモノマーポリペプチド及び使用方法
UY33707A (es) * 2010-11-04 2012-05-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
CN103429620B (zh) * 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
US9574010B2 (en) * 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
CN104203981A (zh) * 2011-12-19 2014-12-10 合成免疫股份有限公司 双特异性抗体分子
BR112015000798A2 (pt) * 2012-07-13 2017-06-27 Zymeworks Inc heterodímeros assimétricos biespecíficos compreendendo construtos anti-cd3
BR112015006824A2 (pt) * 2012-09-27 2017-07-04 Merus B V anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico
CA2906566C (en) * 2013-03-14 2024-09-10 Macrogenics, Inc. Immunoreactive bispecific molecules at immune effector cells expressing an activation receptor
JP6693872B2 (ja) * 2013-07-25 2020-05-13 シトムクス セラピューティクス，インコーポレイティド 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
US20160326249A1 (en) * 2014-01-15 2016-11-10 Zymeworks Inc. Bi-specific cd3 and cd19 antigen-binding constructs
EP4050026A1 (en) * 2014-04-01 2022-08-31 Adimab, LLC Method of obtaining or identifying one or more common light chains for use in preparing a multispecific antibody
US10647768B2 (en) * 2014-05-29 2020-05-12 Macrogenics, Inc. Multi-chain polypeptide-containing tri-specific binding molecules
AU2015279321B2 (en) * 2014-06-27 2021-03-04 Innate Pharma, S.A. Multispecific antigen binding proteins
WO2016122701A1 (en) * 2015-01-26 2016-08-04 Macrogenics, Inc. Anti-dr5 antibodies and molecules comprising dr5-binding domains thereof
RU2733496C2 (ru) * 2015-03-16 2020-10-02 Гельмгольц Центрум Мюнхен - Дойчес Форшунгсцентрум Фюр Гезундхайт Унд Умвельт (Гмбх) Триспецифические связывающие молекулы для лечения вирусной инфекции гепатита в и связанных состояний
JP6840682B2 (ja) * 2015-06-23 2021-03-10 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 多重特異的抗原結合タンパク質
JP2018524373A (ja) * 2015-07-15 2018-08-30 ザイムワークス，インコーポレイテッド 薬物がコンジュゲートされた二重特異性抗原結合コンストラクト
US20180327499A1 (en) * 2015-11-13 2018-11-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti- nkg2d single domain antibodies and uses thereof
CN110944651A (zh) * 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途

Similar Documents

Publication Publication Date Title
JP2020521448A5 (enExample)
JP2021098732A5 (enExample)
JP2021534096A5 (enExample)
JP2021098733A5 (enExample)
JP2020531438A5 (ja) Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質
JP2020522474A5 (enExample)
JP2021035388A5 (ja) Ｃａｉｘ、ａｎｏ１、メソテリン、ｔｒｏｐ２またはクローディン−１８．２を標的にする多重特異性結合タンパク質
JP2020510653A5 (ja) Ｃｅａを標的にする多重特異性結合タンパク質
JP2021512630A5 (enExample)
JP2022515318A5 (enExample)
JP2021523140A5 (enExample)
JP2023538945A5 (enExample)
JP2020103301A5 (enExample)
JP2021522162A5 (enExample)
RU2007145419A (ru) Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
JP2020508997A5 (enExample)
RU2019128134A (ru) Антитело против gprc5d и молекула, содержащая антитело
JP2020533311A5 (ja) ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質
JP2019536430A5 (enExample)
RU2021110369A (ru) Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген
JP2021533169A5 (enExample)
JP2020507328A5 (enExample)
FI3582806T3 (fi) Her2:ta, nkg2d:tä ja cd16:ta sitovia proteiineja
RU2019128204A (ru) Белки, связывающиеся с psma, nkg2d и cd16
RU2020111554A (ru) Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген